The selection of a series of effective drugs for individual patients in advance of drug therapy should increase the success of cancer chemotherapy. The human tumor clonogenic assay was evaluated as a drug sensitivity test mainly in patients with lung cancer. Tumor cells from malignant pleural effusion, tumor-positive bone marrow aspirates, and tumor tissues from the primary or metastases were used as sepcimens. Prior to plating, tumor cells were exposed to 4-hydroperoxy ifosfamide, adriamycin, mitomycin C, methotrerxate, and cisplatin for one hour at graded concentrations which were achievable in man. Of 151 specimens tested, 93(62%) yielded at least 5 colonies in the control plates containing no durgs. Colony growth (≧5/plate) was seen in 80% of squamous cell carcinoma, in 73% of small cell carcinoma, in 62% of adenocarcinoma, and in 40% of large cell carcinoma. Among the 93 specimens with colony growth, 62 yielded more than 30 colonies in the control plates and were put in force for drug sensitivity testing. Of 37 instances in which the clinical response to a certain drug was examined, 34(92%) showed an in vitro-in vivo correlation, showing a true positive rate of 57% and a true negative rate of 100%. In summary, the human tumor clonogenic assay would be an excellent technique for testing the drug sensitivity of the tumor in individual patients tumor.
human tumor clonogenic assay